reports
- Gary Brode
Moody's Ratings announces completion of a periodic review of ratings o...
Announcement of Periodic Review: Moody's Ratings announces completion of a periodic review of ratings of Sanofi. Global Credit Research- 17 Apr 2026. Paris, April 16, 2026-- Moody's Ratings has completed a periodic review of the ratings of Sanofi and other ratings that are associated with this issuer.
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Bristol Myers Squibb Co: 1 director
A director at Bristol Myers Squibb Co sold 30,000 shares at 61.667USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Moody's Ratings says that Lilly's acquisition of Centessa expands neur...
Announcement: Moody's Ratings says that Lilly's acquisition of Centessa expands neuroscience portfolio with mid-stage narcolepsy pipeline. Global Credit Research- 01 Apr 2026. New York, April 01, 2026-- Moody's Ratings said that Eli Lilly and Company's Centessa acquisition adds another long-term growth platform to Lilly's neuroscience franchise with the potential to further diversify the company beyond its market-leading incretin portfolio.
Moody's Ratings announces completion of a periodic review of ratings o...
Announcement of Periodic Review: Moody's Ratings announces completion of a periodic review of ratings of Johnson& Johnson. Global Credit Research- 26 Mar 2026. New York, March 26, 2026-- Moody's Ratings has completed a periodic review of the ratings of Johnson& Johnson and other ratings that are associated with this issuer.
Abbvie Inc: 1 director
A director at Abbvie Inc sold/sold after exercising options 5,230 shares at 233.560USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
Moody's Ratings assigns A2 ratings to AbbVie's senior notes; stable ou...
Moody's Ratings (Moody's) assigned A2 ratings to the new senior unsecured notes issuance of AbbVie Inc. ("AbbVie"). There are no changes to AbbVie's existing ratings including the A2 senior unsecured rating and the Prime-1 short-term rating, or the stable outlook. Proceeds of the offering will pri...
- Curtis Yeung
- Greater China Research Team
Greater China Daily: Monday, February 16, 2026
Top Stories Economics | Money Supply M0 growth was weaker in Jan 26 due to Chinese New Year effects, while M2 growth rose to 9.0% yoy, the highest since 2023. New bank loans surged to Rmb4.71t and new TSF rose to Rmb7.22t, both above consensus forecasts. However, outstanding bank loan growth fell to a record-low 6.1% yoy, highlighting fragile underlying credit demand despite strong front-loaded lending. Sector Update | Healthcare The HSHCI rose 1.8%, outperforming the HSI, which declined by 3.8...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.